RecruitingPhase 2NCT07036601

Phase II Study of THDBH120 Injection in Overweight or Obese Subjects

A Multicenter, Randomized, Double-blind, Placebo-Parallel Controlled, Phase II Study to Evaluate the Efficacy and Safety of THDBH120 Injection in Overweight or Obese Subjects

Sponsor

Tonghua Dongbao Pharmaceutical Co.,Ltd

Enrollment

276 participants

Start Date

Jan 6, 2025

Study Type

INTERVENTIONAL

Conditions

Overweight or obese

Summary

To assess the efficacy and safety of THDBH120 injection compared with placebo in weight reduction in overweight or obese subjects after 26 weeks of treatment.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo of THDBH120 injection and a drug called THDBH120 injection for people with overweight or obese. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.